Drug intelligence / Profile preview

Proximab

Development stage: Preclinical
Lead developer: ProtAb
Administration: Intravenous, Intracoronary

Overview

Proximab is a lead drug candidate developed by ProtAb Ltd., a subsidiary of Hadasit Bio-Holdings Ltd. It is being advanced for broader clinical development and commercialization, targeting the treatment of rheumatoid arthritis and type-1 diabetes. The drug's development has been supported by significant funding, including $3 million from Israeli biotechnology investment groups and approximately $1.5 million in grants from the Israeli Ministry of Industry and Commerce Office of the Chief Scientist.

Beyond the preview

Go deeper on Proximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proximab.

Explore the full profile